268 related articles for article (PubMed ID: 20919845)
21. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Kenefick SJ; Neiger R
J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154
[TBL] [Abstract][Full Text] [Related]
22. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
23. Determination of the concentrations of trilostane and ketotrilostane that inhibit ex vivo canine adrenal gland synthesis of cortisol, corticosterone, and aldosterone.
McGraw AL; Whitley EM; Lee HP; Boothe DM; Behrend EN
Am J Vet Res; 2011 May; 72(5):661-5. PubMed ID: 21529218
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.
Aldridge C; Behrend EN; Kemppainen RJ; Lee-Fowler TM; Martin LG; Ward CR; Bruyette D; Pannu J; Gaillard P; Lee HP
J Vet Intern Med; 2016 Sep; 30(5):1637-1641. PubMed ID: 27425787
[TBL] [Abstract][Full Text] [Related]
26. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
27. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism.
Wenger M; Sieber-Ruckstuhl NS; Müller C; Reusch CE
Am J Vet Res; 2004 Sep; 65(9):1245-50. PubMed ID: 15478772
[TBL] [Abstract][Full Text] [Related]
28. Effects of disease on the results of diagnostic tests for use in detecting hyperadrenocorticism in dogs.
Kaplan AJ; Peterson ME; Kemppainen RJ
J Am Vet Med Assoc; 1995 Aug; 207(4):445-51. PubMed ID: 7591942
[TBL] [Abstract][Full Text] [Related]
29. Comparison of methods to monitor dogs with hypercortisolism treated with trilostane.
Golinelli S; de Marco V; Leal RO; Barbarossa A; Aniballi C; Maietti E; Tardo AM; Galac S; Fracassi F
J Vet Intern Med; 2021 Nov; 35(6):2616-2627. PubMed ID: 34672018
[TBL] [Abstract][Full Text] [Related]
30. The use of trilostane for the treatment of alopecia X in Alaskan malamutes.
Leone F; Cerundolo R; Vercelli A; Lloyd DH
J Am Anim Hosp Assoc; 2005; 41(5):336-42. PubMed ID: 16141187
[TBL] [Abstract][Full Text] [Related]
31. Use of urine cortisol:creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs.
Angles JM; Feldman EC; Nelson RW; Feldman MS
J Am Vet Med Assoc; 1997 Oct; 211(8):1002-4. PubMed ID: 9343543
[TBL] [Abstract][Full Text] [Related]
32. Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats.
Burkhardt WA; Guscetti F; Boretti FS; Ivos Todesco A; Aldajarov N; Lutz TA; Reusch CE; Sieber-Ruckstuhl NS
Domest Anim Endocrinol; 2011 Apr; 40(3):155-64. PubMed ID: 21194873
[TBL] [Abstract][Full Text] [Related]
33. Persistent isolated hypocortisolism following brief treatment with trilostane.
Ramsey IK; Richardson J; Lenard Z; Tebb AJ; Irwin PJ
Aust Vet J; 2008 Dec; 86(12):491-5. PubMed ID: 19076773
[TBL] [Abstract][Full Text] [Related]
34. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Braddock JA; Church DB; Robertson ID; Watson AD
Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
[TBL] [Abstract][Full Text] [Related]
35. The effect of 1 year of trilostane treatment on peripheral lymphocyte subsets in dogs with pituitary-dependent hyperadrenocorticism.
Oda H; Mori A; Shono S; Onozawa E; Sako T
J Vet Med Sci; 2016 Jun; 78(5):851-4. PubMed ID: 26782012
[TBL] [Abstract][Full Text] [Related]
36. Haptoglobin concentrations in dogs undergoing trilostane treatment for hyperadrenocorticism.
McGrotty YL; Arteaga A; Knottenbelt CM; Ramsey IK; Eckersall PD
Vet Clin Pathol; 2005 Sep; 34(3):255-8. PubMed ID: 16134074
[TBL] [Abstract][Full Text] [Related]
37. Use of basal serum or plasma cortisol concentrations to rule out a diagnosis of hypoadrenocorticism in dogs: 123 cases (2000-2005).
Lennon EM; Boyle TE; Hutchins RG; Friedenthal A; Correa MT; Bissett SA; Moses LS; Papich MG; Birkenheuer AJ
J Am Vet Med Assoc; 2007 Aug; 231(3):413-6. PubMed ID: 17669044
[TBL] [Abstract][Full Text] [Related]
38. Use of the urine cortisol: creatinine ratio to monitor treatment response in dogs with pituitary-dependent hyperadrenocorticism.
Guptill L; Scott-Moncrieff JC; Bottoms G; Glickman L; Johnson M; Glickman N; Nelson R; Bertoy E
J Am Vet Med Assoc; 1997 Apr; 210(8):1158-61. PubMed ID: 9108922
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two low-dose dexamethasone suppression protocols as screening and discrimination tests in dogs with hyperadrenocorticism.
Mack RE; Feldman EC
J Am Vet Med Assoc; 1990 Dec; 197(12):1603-6. PubMed ID: 2177458
[TBL] [Abstract][Full Text] [Related]
40. ACTH-independent hyperadrenocorticism due to food-dependent hypercortisolemia in a dog: a case report.
Galac S; Kars VJ; Voorhout G; Mol JA; Kooistra HS
Vet J; 2008 Jul; 177(1):141-3. PubMed ID: 17572120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
